Physician profile
James J Lee
NPI 1790773471
$32,745.39
in general payments reported to CMS, 2019-2025
74 companies · $1,872 in 2025
The $1,872 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $607 · 2020: $728 · 2021: $3,388 · 2022: $4,330 · 2023: $2,404 · 2024: $19K · 2025: $1,872.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,060 · Food and Beverage: $6,808 · Consulting Fee: $6,020 · Travel and Lodging: $2,704 · Education: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,060.00 |
| Food and Beverage | $6,807.53 |
| Consulting Fee | $6,020.00 |
| Travel and Lodging | $2,704.47 |
| Education | $101.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $9,398.38 | 2021-2025 | |
| Gilead Sciences, INC. | $7,933.81 | 2022-2025 | Trodelvy |
| Incyte Corporation | $3,039.56 | 2019-2024 | Jakafi, Monjuvi |
| Regeneron Healthcare Solutions, INC. | $2,345.11 | 2022-2025 | Libtayo |
| Novartis Pharmaceuticals Corporation | $748.80 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $719.26 | 2019-2025 | Opdivo, Eliquis |
| Pfizer INC. | $694.79 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $612.52 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Abbvie INC. | $609.63 | 2020-2025 | |
| Genentech USA, INC. | $540.14 | 2020-2025 | Polivy, Lunsumio, Phesgo |
| Janssen Biotech, INC. | $483.93 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Takeda Pharmaceuticals U.S.A., INC. | $467.54 | 2021-2025 | Ninlaro, Alunbrig, Fruzaqla |
| Astellas Pharma US INC | $315.39 | 2020-2025 | Xtandi, Padcev, Veozah |
| Daiichi Sankyo INC. | $306.77 | 2023-2025 | Enhertu, Injectafer |
| Glaxosmithkline, LLC. | $266.21 | 2019-2025 | Jemperli, Zejula, Ojjaara |
Show all 71 companies
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.